| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
David S Tierney is Director at CPRX, with reported holdings spanning 2 companies. David S Tierney's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $111K at current prices.
Our model assigns David S Tierney a middling insider score of 53/100, based on 8 past trades. Over a 12-month horizon, 42.9% of those trades were profitable, with an average 12-month return of -10.7%.
David S Tierney's largest disclosed position is in ZVRA as Director, worth about $111K. Net of sales, the ZVRA filings show accumulation of 25,000 shares.
David S Tierney has 36 Form 4 filings on record from April 2015 to December 2025, across 2 companies: Director at Catalyst Pharmaceuticals (CPRX), 2022–2025; Director at Zevra Therapeutics (ZVRA), 2015–2023.
The 49 reported transactions were 17 option exercises, 16 option or other derivative awards, 9 open-market purchases and 5 open-market sales, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 6 purchases worth about $111K and 5 sales worth about $2.4M.
The largest open-market purchase was 5,000 shares of ZVRA at an average $11.00 on April 21, 2015, about $55K.
The largest open-market sale was 50,000 shares of CPRX at an average $13.32 on December 12, 2023, about $666K. Twelve months later CPRX was up 65%.
None of the 5 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 27, 2025 | CPRX Catalyst Pharmaceuticals, Inc. | Director | Sale+OE | 26,000 | $20.20 | $525,200.00 | -6.4% | +16.8% | - | |
| Aug 21, 2024 | CPRX Catalyst Pharmaceuticals, Inc. | Director | Sale+OE | 15,000 | $20.10 | $301,455.00 | -4.1% | +4.5% | +0.4% | |
| Apr 8, 2024 | CPRX Catalyst Pharmaceuticals, Inc. | Director | Sale+OE | 25,000 | $15.68 | $392,000.00 | -6.7% | -0.4% | +38.0% | |
| Dec 12, 2023 | CPRX Catalyst Pharmaceuticals, Inc. | Director | Sale+OE | 50,000 | $13.33 | $666,250.00 | -13.0% | +20.6% | +64.6% | |
| Apr 5, 2023 | CPRX Catalyst Pharmaceuticals, Inc. | Director | Sale+OE | 30,000 | $16.83 | $504,900.00 | -8.7% | -25.2% | -10.7% | |
| Mar 9, 2023 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 5,000 | $4.15 | $20,731.50 | +85.7% | +27.3% | +43.5% | |
| May 25, 2022 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 2,000 | $4.39 | $8,780.00 | +52.2% | +26.0% | +12.9% | |
| Nov 30, 2021 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 2,000 | $7.79 | $15,578.00 | +109.0% | -24.3% | -39.2% | |
| Aug 18, 2020 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 10,000 | $0.65 | $6,531.75 | +51.6% | - | - | |
| Mar 20, 2017 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 1,000 | $4.20 | $4,199.90 | +20.0% | - | - |